Atezolizumab,nivolumab,Pembrolizumab,Ipilimumab
merck,roche,bms
['rcc,(-irccs),(-srcc),(-urcc)', 'pembro']
very well balanced explanation. why pembrolizumab is doing ok ( for dfs and may not get os ) and others are not in adjuvant rcc #esmo22 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists